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ABSTRACT 
Genome-wide association studies have identified breast cancer risk variants in over 150 
genomic regions, but the mechanisms underlying risk remain largely unknown. These 
regions were explored by combining association analysis with in silico genomic feature 
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annotations. We defined 205 independent risk-associated signals with the set of credible 
causal variants (CCVs) in each one. In parallel, we used a Bayesian approach (PAINTOR) that 
combines genetic association, linkage disequilibrium, and enriched genomic features to 
determine variants with high posterior probabilities of being causal. Potentially causal 
variants were significantly over-represented in active gene regulatory regions and 
transcription factor binding sites. We applied our INQUSIT pipeline for prioritizing genes as 
targets of those potentially causal variants, using gene expression (eQTL), chromatin 
interaction and functional annotations. Known cancer drivers, transcription factors and 
genes in the developmental, apoptosis, immune system and DNA integrity checkpoint gene 
ontology pathways, were over-represented among the highest confidence target genes. 
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INTRODUCTION 
Genome-wide association studies (GWAS) have identified genetic variants associated with 
breast cancer risk in more than 150 genomic regions 1,2. However, the variants and genes 
driving these associations are mostly unknown, with fewer than 20 regions studied in detail 
3-20. Here, we aimed to fine-map all known breast cancer susceptibility regions using dense 
genotype data on > 217K subjects participating in the Breast Cancer Association Consortium 
(BCAC) and the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). All samples 
were genotyped using the OncoArrayTM 1,2,21 or the iCOGS chip 22,23. Stepwise multinomial 
logistic regression was used to identify independent association signals in each region and 
define credible causal variants (CCVs) within each signal. We found genomic features 
significantly overlapping the CCVs. We then used a Bayesian approach, integrating genomic 
features and genetic associations, to refine the set of likely causal variants and calculate 
their posterior probabilities. Finally, we integrated genetic and in silico epigenetic, 
expression and chromatin conformation data to infer the likely target genes of each signal. 
 
RESULTS 
Most breast cancer genomic regions contain multiple independent risk-associated signals 
We included 109,900 breast cancer cases and 88,937 controls, all of European ancestry, 
from 75 studies in the BCAC. Genotypes (directly observed or imputed) were available for 
639,118 single nucleotide polymorphisms (SNPs), deletion/insertions, and copy number 
variants (CNVs) with minor allele frequency (MAF) ≥ 0.1% within 152, previously defined, 
risk-associated regions (Supplementary Table 1; Figure 1). Multivariate logistic regression 
confirmed associations for 150/152 regions at a p-value < 10-4 significance threshold 
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(Supplementary Table 2A). To determine the number of independent risk signals within 
each region we applied stepwise multinomial logistic regression, deriving the association of 
each variant, conditional on the more significant ones, in order of statistical significance. 
Finally, we defined CCVs in each signal as variants with conditional p-values within two 
orders of magnitude of the index variant 24. We classified the evidence for each 
independent signal, and its CCVs, as either strong (conditional p-values <10-6) or moderate 
(10-6 < conditional p-values <10-4). 
 
From the 150 genomic regions we identified 352 independent risk signals containing 13,367 
CCVs, 7,394 of these were within the 196 strong-evidence signals across 129 regions 
(Figures 2A-B). The number of signals per region ranged from 1 to 11, with 79 (53%) 
containing multiple signals. We noted a wide range of CCVs per signal, but in 42 signals 
there was only a single CCV: for these signals, the simplest hypothesis is that the CCV is 
causal (Figures 2C-D, Table 1). Furthermore, within signals with few CCVs (<10), the mean 
scaled CADD score was higher than in signals with more CCVs (13.1 Vs 6.7 for CCVs in exons; 
Pttest = 2.7x10
-4) suggesting that these are more likely to be functional. 
 
The majority of breast tumors express the estrogen receptor (ER-positive), but ~20% do not 
(ER-negative); these two tumor types have distinct biological and clinical characteristics 25. 
Using a case-only analysis for the 196 strong-evidence signals, we found 66 signals (34%; 
containing 1,238 CCVs) where the lead variant conferred a greater relative-risk of 
developing ER-positive tumors (false discovery rate, FDR 5%), and 29 (15%; 646 CCVs) where 
the lead variant conferred a greater risk of ER-negative cancer tumors (FDR 5%) 
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(Supplementary Table 2B, Figure 2E). The remaining 101 signals (51%, 5,510 CCVs) showed 
no difference by ER status (referred to as ER-neutral). 
 
Patients with BRCA1 mutations are more likely to develop ER-negative tumors 26. Hence, to 
increase our power to identify ER-negative signals, we performed a fixed-effects meta-
analysis, combining association results from BRCA1 mutation carriers in CIMBA with the 
BCAC ER-negative association results. This meta-analysis identified ten additional signals, 
seven ER-negative and three ER-neutral, making 206 strong-evidence signals (17% ER-
negative) containing 7,652 CCVs in total (Figure 2F). More than one quarter of the CCVs 
(2,277) were accounted for by one signal, resulting from strong linkage disequilibrium with a 
copy number variant. The remaining analyses focused on the other 205 strong signals across 
128 regions (Supplementary Table 2C). 
The proportion of the familial relative risk of breast cancer (FRR) explained by all 206 strong 
signals was 20.6%, compared with 17.6% when only the lead SNP for each region was 
considered. The proportion of the FRR explained increased by a further 3% (to 23.6%) when 
all 352 signals were considered (Supplementary Table 2D). 
CCVs are over-represented in active gene-regulatory regions and transcription factor 
binding sites. 
We constructed a database of mapped genomic-features in seven primary cells derived 
from normal breast and 19 breast cell lines using publicly available data, resulting in 811 
annotation tracks in total. These ranged from general features, such as whether a variant 
was in an exon or in open chromatin, to more specific features, such a cell-specific TF 
binding or histone mark (determined through ChIP-Seq experiments) in breast-derived cells 
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or cell lines. Using logistic regression, we examined the overlap of these genomic-features 
with the positions of 5,117 CCVs in the 195 strong-evidence BCAC signals versus the 
positions of 622,903 variants excluded as credible candidates in the same regions 
(Supplementary Figure 1A, Supplementary Table 3). We found significant enrichment of 
CCVs (FDR 5%) in the following genomic-features: 
 
(i) Open chromatin (determined by DNase-seq and FAIRE-seq) in ER-positive breast cancer 
cell-lines and normal breast (Figure 3A). Conversely, we found depletion of CCVs within 
heterochromatin (determined by the H3K9me3 mark in normal breast, and by chromatin-
state in ER-positive cells 27). 
 
(ii) Actively transcribed genes in normal breast and ER-positive cell lines (defined by 
H3K36me3 or H3K79me2 histone marks, Figure 3A). Enrichment was larger for ER-neutral 
CCVs than for those affecting either ER-positive or ER-negative tumors. 
 
(iii) Gene regulatory regions. CCVs overlapped distal gene regulatory elements in ER-positive 
breast cancer cells lines (defined by H3K4me1 or H3K27ac marks, Figure 3B). This was 
confirmed using the ENCODE definition of active enhancers in MCF-7 cells (enhancer-like 
regions defined by combining DNase and H3K27ac marks), as well as the definition of 28 and 
27 (Supplementary Table 3). Under these more stringent definitions, enrichment among ER-
positive CCVs was significantly larger than ER-negative or ER-neutral CCVs. Data from 27, 
showed that 73% of active enhancer regions overlapped by ER-positive CCVs in ER-positive 
cells (MCF-7), are inactive in the normal HMEC breast cell line; thus, these enhancers appear 
to be MCF-7-specific. 
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We also detected significant enrichment of CCVs in active promoters in ER-positive cells 
(defined by H3K4me3 marks in T-47D), although the evidence for this effect was weaker 
than for distal regulatory elements (defined by H3K27ac marks in MCF-7, Figure 3B). Only 
ER-positive CCVs were significantly enriched in T-47D active promoters. Conversely, CCVs 
were depleted among repressed gene-regulatory elements (defined by H3K27me3 marks) in 
normal breast (Figure 3B). As a control, we performed similar analyses with autoimmune 
disease CCVs 29 (Methods) and relevant B and T cells (Figures 3B-E). The strongest evidence 
of enrichment of breast cancer CCVs was found at regulatory regions active in ER-positive 
cells (Figure 3B), whereas enrichment of autoimmune CCVs was in regulatory regions active 
in B and T cells (Figure 3E). We also compared the enrichment of our CCVs in enhancer-like 
and promoter-like regions (defined by ENCODE; Supplementary Figure 1B). The strongest 
evidence of enrichment of ER-positive CCVs in enhancer-like regions was found in MCF-7 
cells, the only ER-positive cell line in ENCODE (Supplementary Figure 1B). These results 
highlight both the tissue- and disease-specificity of these histone marked gene regulatory 
regions. 
 
(iv) We observed significant enrichment of CCVs in the binding sites for 40 transcription 
factor binding sites(TFBS) determined by ChIP-Seq (Figures 3F-H). The majority of the 
experiments were performed in ER-positive cell lines (90 TFBSs, 20 with data in ER-negative 
cell lines, 76 in ER-positive cell lines, and 16 in normal breast). These TFBSs overlap each 
other and histone marks of active regulatory regions (Supplementary Figure 2). Enrichment 
in five TFBSs (ESR1, FOXA1, GATA3, TCF7L2, E2F1) has been previously reported 2,30. All 40 
TFBSs were significantly enriched in ER-positive CCVs (Figure 3F), seven were also enriched 
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in ER-negative CCVs and nine in ER-neutral CCVs (Figures 3G-H). ESR1, FOXA1, GATA3 and 
EP300 TFBSs were enriched in all CCV ER-subtypes. However, the enrichment for ESR1, 
FOXA1 or GATA3 was stronger for ER-positive CCVs than for ER-negative or ER-neutral. 
 
CCVs significantly overlap consensus transcription factor binding motifs 
We investigated whether CCVs were also enriched within consensus transcription factor 
binding motifs by conducting a motif-search within active regulatory regions (ER-positive 
CCVs at H3K4me1 marks in MCF-7). We identified 30 motifs, from eight transcription factor 
families, with enrichment in ER-positive CCVs (FDR 10%, Supplementary Table 4A) and a 
further five motifs depleted among ER-positive CCVs. To assess whether the motifs 
appeared more frequently than by chance at active regulatory regions overlapped by our 
ER-positive CCVs, we compared motif-presence in a set of randomized control sequences 
(Methods). Thirteen of 30 motifs were more frequent at active regulatory regions with ER-
positive CCV enrichment; these included seven homeodomain motifs and two fork head 
factors (Supplementary Table 4B). 
 
When we looked at the change in predicted binding affinity, 57 ER-positive signals (86%) 
included at least one CCV predicted to modify the binding affinity of the enriched TFBSs (≥2-
fold, Supplementary Table 4C). Forty-eight ER-positive signals (73%) had at least one CCV 
predicted to modify the binding affinity >10-fold. This analysis validates previous reports of 
breast cancer causal variants that alter DNA binding affinity for FOXA1 3,30 
 
Bayesian fine -mapping incorporating functional annotations and linkage disequilibrium 
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As an alternative statistical approach for inferring likely causal variants, we applied PAINTOR 
31 to the same 128 regions (Figure 1). In brief, PAINTOR integrates genetic association 
results, linkage disequilibrium (LD) structure, and enriched genomic features in an empirical 
Bayes framework and derives the posterior probability of each variant being causal, 
conditional on available data. To eliminate artifacts due to differences in genotyping and 
imputation across platforms, we restricted PAINTOR analyses to cases and controls typed 
using the OncoArray (61% of the total). We identified seven variants with high posterior 
probability (HPP ≥ 80%) of being causal for overall breast cancer and ten for the ER-positive 
subtype (Table 1); two of these had HPP > 80% for both ER-positive and overall breast 
cancer. These 15 HPP variants (HPPVs; ≥ 80%) were distributed across 13 regions. We also 
identified an additional 35 variants in 25 regions with HPP (≥ 50% and < 80%) for ER-
positive, ER-negative, or overall breast cancer (Figure 2G).  
 
Consistent with the CCV analysis, we found evidence that most regions contained multiple 
HPPVs; the sum of posterior probabilities across all variants in a region (an estimate of the 
number of distinct causal variants in the region) was > 2.0 for 84/86 regions analyzed for 
overall breast cancer, with a maximum of 16.1 and a mean of 6.4. For ER-positive cancer, 
46/47 regions had total posterior probability > 2.0 (maximum 18.3, mean 6.5) and for ER-
negative, 17/23 regions had total posterior probability > 2.0 (maximum 9.1, mean 3.2). 
 
Although for many regions we were not able to identify HPP variants, we were able to 
reduce the proportion of variants needed to account for 80% of the total posterior 
probability in a region to under 5% for 65 regions for overall, 43 for ER-positive, and 18 for 
ER-negative breast cancer (Supplementary Figure 3A-C). PAINTOR analyses were also able 
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to reduce the set of likely causal variants in many cases. After summing the posterior 
probabilities for CCVs in each of the overall breast cancer signals, 39/100 strong-evidence 
signals had a total posterior probability > 1.0. The number of CCVs in these signals ranged 
from 1 to 375 (median 24), but the number of variants needed to capture 95% of the total 
PP in each signal ranged from 1 to 115 (median 12), representing an average reduction of 
43% in the number of variants needed to capture the signal. 
 
PAINTOR and CCV analyses were generally consistent, yet complementary. Only 3.3% of 
variants outside of the set of strong-signal CCVs for overall breast cancer had posterior 
probability > 1%, and only 48 (0.013%) of these had posterior probability > 30% 
(Supplementary Figure 3D). At ER-positive and ER-negative signals respectively, 3.1% and 
1.6% of the non-CCVs at strong signals had posterior probability > 1%, and 40 (0.019%) and 
3 (0.003%) of these had posterior probability > 30% (Figures S3E-F). For the non-CCVs at 
strong-evidence signals with posterior probability > 30%, the relatively high posterior 
probability may be driven by the addition of functional annotation. Indeed, the 
incorporation of functional annotations more than doubled the posterior probability for 
64/88 variants when compared to a PAINTOR model with no functional annotations.  
 
CCVs co-localize with variants controlling local gene expression 
We used four breast-specific expression quantitative trait loci (eQTL) data sets to identify a 
credible set of variants associated with differences in gene expression (eVariants): tumor 
tissue from the Nurses’ Health Study (NHS) 32 and The Cancer Genome Atlas (TCGA) 33, and 
normal breast tissue from the NHS and the Molecular Taxonomy of Breast Cancer 
International Consortium (METABRIC) 34. We then examined the overlap of eVariants (for 
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each gene eVariants were defined as those variants that had a p-value within two orders of 
magnitude of the variant most significantly associated with that gene’s expression) with 
CCVs (Methods). There was significant overlap of CCVs with eVariants from both the NHS 
normal and breast cancer tissue studies (normal breast OR = 2.70, p-value = 1.7×10-5; tumor 
tissue OR = 2.34, p-value = 2.6×10-4; Supplementary Table 3). ER-neutral CCVs overlapped 
with eVariants in normal tissue more frequently than did ER-positive and ER-negative CCVs 
(ORER-neutral = 3.51, p-value = 1.3×10
-5). Cancer risk CCVs overlapped credible eVariants in 
128/205 (62%) signals in at least one of the datasets (Supplementary Table 5A-B). Sixteen 
additional variants with PP ≥ 30%, not included among the CCVs, also overlapped with a 
credible eVariant (Supplementary Table 5A-B). 
 
Transcription factors and known somatic breast cancer drivers are overrepresented 
among prioritized target genes  
We assumed that causal variants function by affecting the behavior of a local target gene. 
However, it is challenging to define target genes or to determine how they may be affected 
by the causal variant. Few potentially causal variants directly affect protein coding: we 
observed 67/5,375 CCVs, and 19/137 HPPVs (≥ 30%) in protein-coding regions. Of these, 33 
(0.61%) were predicted to create a missense change, one a frameshift, and another a stop-
gain, while 30 were synonymous (0.59%, Supplementary Table 5C). Four hundred and 
ninety-nine CCVs at 94 signals, and four additional HPPV (≥ 30%), are predicted to create 
new splice sites or activate cryptic splice sites in 126 genes (Supplementary Table 5D). 
These results are consistent with previous observations that majority of common 
susceptibility variants are regulatory. 
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We applied an updated version of our pipeline INQUISIT - integrated expression quantitative 
trait and in-silico prediction of GWAS targets) 2 to prioritize potential target genes from 
5,375 CCVs in strong signals and all 138 HPPVs (≥ 30%; Supplementary Table 2C). The 
pipeline predicted 1,204 target genes from 124/128 genomic regions examined. As a 
validation we examined the overlap between INQUISIT predictions and 278 established 
breast cancer driver genes 35-39. Cancer driver genes were over-represented among high 
confidence (Level 1) targets; a 5-fold increase over expected from CCVs and 15-fold from 
HPPVs; p-value= 1×10-6; Supplementary Figure 4A). Notably, thirteen cancer driver genes 
(ATAD2, CASP8, CCND1, CHEK2, ESR1, FGFR2, GATA3, MAP3K1, MYC, SETBP1, TBX3, XBP1 
and ZFP36L1) were predicted from the HPPVs derived from PAINTOR. Cancer driver gene 
status was consequently included as an additional weighting factor in the INQUISIT pipeline. 
TF genes 40 were also enriched amongst high-confidence targets predicted from both CCVs 
(2-fold, p-value = 4.6×10-4) and HPPVs (2.5-fold, p-value = 1.8×10-2, Supplementary Figure 
4A). 
 
In total INQUISIT identified 191 target genes supported by strong evidence (Supplementary 
Table 6). Significantly more genes were targeted by multiple independent signals (N = 165) 
than expected by chance (p-value = 4.3×10-8, Supplementary Figure 4B, Figure 4). Six high-
confidence predictions came only from HPPVs, although three of these (IGFBP5, POMGNT1 
and WDYHV1) had been predicted at lower confidence from CCVs. Target genes included 20 
that were prioritized via potential coding/splicing changes (Supplementary Table 7), ten via 
promoter variants (Supplementary Table 8), and 180 via distal regulatory variants 
(Supplementary Table 9). We illustrate genes prioritized via multiple lines of evidence in 
Figure 4A. 
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Three examples of INQUISIT using genomic features to identify predict target genes. Based 
on capture Hi-C and ChIA-PET chromatin interaction data, NRIP1 is a predicted target of 
intergenic CCVs and HPPVs at chr21q21 (Supplementary Figure 5A). Multiple target genes 
were predicted at chr22q12, including the driver genes CHEK2 and XBP1 (Supplementary 
Figure 5B). A third example at chr12q24.31 is a more complicated scenario with two Level 1 
targets: RPLP0 41 and a modulator of mammary progenitor cell expansion, MSI1 42 
(Supplementary Figure 5C). 
 
Target gene pathways include DNA integrity-checkpoint, apoptosis, developmental 
processes and the immune system 
We performed pathway analysis to identify common processes using INQUSIT high 
confidence target protein-coding genes (Figure 5A) and identified 488 Gene Ontology terms 
and 307 pathways at an FDR of 5% (Supplementary Table 10). These were grouped into 98 
themes by common ancestor Gene Ontology terms, pathways, or transcription factor 
classes (Figure 5B). We found that 23% (14/60) of the ER-positive target genes were 
classified within developmental process pathways (including mammary development), 18% 
in immune system and a further 17% in nuclear receptors pathways. Of genes targeted by 
ER-neutral signals, 21% (18/87) were classified in developmental process pathways, 19% in 
in immune system pathways, and a further 18% in apoptotic process. The top themes of 
genes targeted by ER-negative signals were DNA integrity checkpoint and immune system, 
each containing 19% (7/37) genes, and apoptotic processes (16%). 
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Novel pathways revealed by this study include TNF-related apoptosis-inducing ligand (TRAIL) 
signaling, the AP-2 transcription factors pathway, and regulation of IB kinase/NF-B 
signaling. Of note, the latter of these is specifically overrepresented among ER-negative 
target genes. We also found significant overrepresentation of additional carcinogenesis-
linked pathways including cAMP, NOTCH, PI3K, RAS, WNT/Beta-catenin, and of receptor 
tyrosine kinases signaling, including FGFR, EGFR, or TGFBR 43-47. Finally, our target genes are 
also significantly overrepresented in DNA damage checkpoint, DNA repair pathways, as well 
as programmed cell death pathways, such as apoptotic process, regulated necrosis, and 
death receptor signaling-related pathways. 
 
DISCUSSION 
We have performed multiple, complementary analyses on 150 breast cancer associated 
regions, originally found by GWAS, and identified 362 independent risk signals, 205 of these 
with high confidence (p-value < 10-6). The inclusion of these new variants increases the 
explained proportion of familial risk by 6% when compared to that explained by the lead 
signals alone.  
We observed most regions contain multiple independent signals, the greatest number 
(nine) in the region surrounding ESR1 and its co-regulated genes, and on 2q35, where 
IGFBP5 appears to be a key target. We have used two complementary approaches to 
identify likely causal variants within each region: a Bayesian approach, PAINTOR, which 
integrated genetic associations, LD and informative genomic features, providing 
complementary evidence supporting most associations found by the more traditional, 
multinomial regression approach, and also identified additional variants. Specifically, the 
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Bayesian method highlighted 15 variants that are highly likely to be causal (HPP ≥ 80%). 
From these approaches we have identified a single variant, likely to be causal, at each of 34 
signals (Table 1). Of these, only rs16991615 (MCM8 NP_115874.3:p.E341K) and rs7153397 
(CCDC88C NM_001080414.2:c.5058+1342G>A, a cryptic splice-donor site) were predicted to 
affect protein-coding sequences. However, in other signals we also identified four coding 
changes previously recognized as deleterious, including the stop-gain rs11571833 (BRCA2 
NP_000050.2:p.K3326*, Meeks et al., 2016)48 and two CHEK2 coding variants; the frameshift 
rs555607708 49,50, and a missense variant, rs17879961 51,52. In addition, a splicing variant, 
rs10069690, in TERT results in the truncated protein INS1b 19, decreased telomerase 
activity, telomere shortening, and increased DNA damage response 53  
 
Having identified potential causal variants within each signal, we aimed to uncover their 
functions at the DNA level and as well as trying to predict their target gene(s). Looking 
across all 150 regions, a notable feature is that many likely causal variants implicated in ER-
positive cancer risk, lie in gene-regulatory regions marked as open and active in ER-positive 
breast cells, but not in other cell types. Moreover, a significant proportion of potential 
causal variants overlap the binding sites for transcription factor proteins (n=40 from ChIP-
Seq) and co-regulators (n=64 with addition of computationally derived motifs). 
Furthermore, nine proteins also appear in the list of high-confidence target genes, hence 
the following genes and their products have been implicated by two different approaches: 
CREBBP, EP300, ESR1, FOXI1, GATA3, MEF2B, MYC, NRIP1 and TCF7L2. Most proteins 
encoded by these genes already have established roles in estrogen signaling. CREBBP, 
EP300, ESR1, GATA3, and MYC are also known cancer driver genes that are frequently 
somatically mutated in breast tumors. 
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In contrast to ER-positive signals, we identified fewer genomic features enriched in ER-
negative signals. This may reflect the common molecular mechanisms underlying their 
development, but the power of this study was limited, despite including as many patients 
with ER-negative tumors as possible, from the BCAC and CIMBA consortia. Less than 20% of 
genomic signals confer a greater risk of ER-negative cancer and there is little publicly 
available ChIP-Seq data on ER-negative breast cancer cell lines. The heterogeneity of ER-
negative tumors may also have limited our power. Nevertheless, we have identified 35 
target genes for ER-negative likely causal variants. Some of these already had functional 
evidence supporting their role: including CASP8 54 and MDM4 55. Most targets, however, 
currently have no reported function in ER-negative breast cancer development. 
 
Finally, we examined the gene-ontology pathways in which target genes most often lie. Of 
note, 14% (25/180) of all high-confidence target genes and 19% of ER-negative target 
predictions are in immune system pathways. Among the significantly enriched pathways 
were T cell activation, interleukin signaling, Toll-like receptor cascades, and I-B kinase/NF-
B signaling, as well as processes leading to activation and perpetuation of the innate 
immune system. The link between immunity, inflammation and tumorigenesis has been 
extensively studied 56, although not primarily in the context of susceptibility. Five ER-
negative high confidence target genes (ALK, CASP8, CFLAR, ESR1, TNFSF10) lie in the I-B 
kinase/NF-B signaling pathway. Interestingly, ER-negative cells have high levels of NF-kB 
activity when compared to ER-positive 57. A recent expression–methylation analysis on 
breast cancer tumor tissue also identified clusters of genes correlated with DNA methylation 
levels, one enriched in ER signaling genes, and a second in immune pathway genes 58. 
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These analyses provide strong evidence for more than 200 independent breast cancer risk 
signals, identify the plausible cancer variants and define likely target genes for the majority 
of these. However, notwithstanding the enrichment of certain pathways and transcription 
factors, the biological basis underlying most of these signals remains poorly understood. 
Our analyses provide a rational basis for such future studies into the biology underlying 
breast cancer susceptibility. 
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METHODS 
Study samples 
Epidemiological data for European women were obtained from 75 breast cancer case-control studies 
participating in the Breast Cancer Association Consortium (BCAC) (cases: 40,285 iCOGS, 69,615 
OncoArray; cases with ER status available: 29,561 iCOGS, 55,081 OncoArray); controls: 38,058 iCOGS, 
50,879 OncoArray). Details of the participating studies, genotyping calling and quality control are 
given in 2,22,23, respectively. Epidemiological data for BRCA1 mutation carriers were obtained from 60 
studies providing data to the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) 
(affected 1,591 iCOGS, 7,772 OncoArray; unaffected 1,665 iCOGS, 7,780 OncoArray). This dataset has 
been described in detail previously 1,59,60. All studies provided samples of European ancestry. Any non-
European samples were excluded from analyses. 
 
Variant selection and genotyping  
Similar approaches were used to select variants for inclusion on the iCOGS and OncoArray, which are 
described in detail elsewhere 2,21. Both arrays including a dense coverage of variants across known 
susceptibility regions (at the time of their design), with sparser coverage of the rest of the genome.  
Twenty-one known susceptibility regions were selected for dense genotyping using iCOGS and 73 
regions using the Oncoarray: the regions were 1Mb intervals centred on the published lead GWAS hit 
(combined into larger intervals where these overlapped). For iCOGS: all known variants from the 
March 2010 release of the 1000 Genomes Project with MAF > 0.02 in Europeans were identified, and 
all those correlated with the published GWAS variants at r2 > 0.1 together with a set of variants 
designed to tag all remaining variants at r2 > 0.9 were selected to be included in the array. 
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(http://ccge.medschl.cam.ac.uk/files/2014/03/iCOGS_detailed_lists_ALL1.pdf). For Oncoarray, all 
designable variants correlated with the known hits at r2 > 0.6, plus all variants from lists of potentially 
functional variants on RegulomeDB, and a set of variants designed to tag all remaining variants at r2 > 
0.9 were selected. In total, across the 152 regions considered here, 26,978 iCOGS and 58,339 
OncoArray genotyped variants passed QC criteria.  
We imputed genotypes for all remaining variants using IMPUTE2 61 and the October 2014 release of 
the 1000 Genomes Project as a reference. Imputation was conducted independently in the iCOGS and 
OncoArray subsets. To improve accuracy at low frequency variants, we used the standard IMPUTE2 
MCMC algorithm for follow-up imputation, which includes no pre-phasing of the genotypes and 
increasing both the buffer regions and the number of haplotypes to use as templates (more detailed 
description of the parameters used can be found in 21).  We thus genotyped or successfully imputed 
639,118 variants (all with imputation info score ≥ 0.3 and minor allele frequency (MAF) ≥ 0.001 in 
both iCOGS and OncoArray datasets). Imputation summaries, and coverage for each of the analyzed 
regions stratified by allele frequency can be found in Supplementary Table 1B. 
 
BCAC Statistical analyses 
Per-allele odds ratios (OR) and standard errors (SE) were estimated for each variant using logistic 
regression. We ran this analysis separately for iCOGS and OncoArray, and for overall, ER-positive and 
ER-negative breast cancer. The association between each variant and breast cancer risk was adjusted 
by study (iCOGS) or country (OncoArray), and eight (iCOGS) or ten (OncoArray) ancestry-informative 
principal components. The statistical significance for each variant was derived using a Wald test. 
 
Defining appropriate significance thresholds for association signals 
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To establish an appropriate significance threshold for independent signals, all variants evaluated in 
the meta-analysis were included in logistic forward selection regression analyses for overall breast 
cancer risk in iCOGS, run independently for each region. We evaluated five p-value thresholds for 
inclusion: < 1×10−4, < 1×10-5, < 1×10-6, < 1×10-7, and < 1×10-8. The most parsimonious iCOGS models 
were tested in OncoArray, and the false discovery rate (FDR) at 1% level for each threshold estimated 
using the Benjamini-Hochberg procedure. At a 1% FDR threshold: 72% of associations, significant at 
p<10-4, were replicated on iCOGS and 94% of associations, significant at p<10-6, were replicated on 
OncoArray. Based on these results, two categories were defined: strong-evidence signals (conditional 
p-values <10-6 in the final model), and moderate-evidence signals (conditional p-values <10-4 and ≥10-6 
in the final model) 
 
Identification of independent signals  
To identify independent signals, we ran multinomial stepwise regression analyses, separately in iCOGS 
and OncoArray, for all variants displaying evidence of association (Nvariants = 202,749). We selected two 
sets of well imputed variants (imputation info score ≥ 0.3 in both iCOGS and OncoArray): (a) common 
and low frequency variants (MAF ≥ 0.01) with logistic regression p-value inclusion threshold ≤0.05 in 
either the iCOGS or OncoArray datasets for at least one of the three phenotypes: overall, ER-positive 
and ER-negative breast cancer; and (b) rarer variants (MAF ≥ 0.001 and < 0.01), with logistic 
regression inclusion p-value ≤ 0.0001. The same parameters used for adjustment in logistic regression 
were used in the multinomial regression analysis (R function multinom). The multinomial regression 
estimates were combined using a fixed-effects meta-analysis weighted by the inverse variance. 
Variants with the lowest conditional p-value from the meta-analysis of both European cohorts at each 
step were included into the multinomial regression model. However, if the new variant to be included 
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in the model caused collinearity problems due to high correlation with an already selected variant, or 
showed high heterogeneity (p-value < 10-4) between iCOGS and OncoArray after being conditioned by 
the variant(s) in the model; we dropped the new variant and repeated this process.  
 
At 105 of 152 evaluated regions the main signal demonstrated genome-wide significance, while 44 
were marginally significant (9.89×10-5 ≥ p-value > 5×10-8). For two regions there were no variants 
significant at p<10-4 (chr14:104712261-105712261; rs10623258 multinomial regression p-value = 
2.32×10-4; chr19:10923703-11923703, rs322144, multinomial regression p-value = 3.90×10-3). Four 
main differences in the datasets used here and in the previous paper may account for this: (i) our 
previous paper 2 included data from 11 additional GWAS (14,910 cases and 17,588 controls) that have 
not been included in the present analysis in order to minimize differences in array coverage, and 
because ER-status data were substantially incomplete and individual level data were not available for 
all GWAS; (ii) the present analysis was based on estimating separate risks for ER-positive and ER-
negative disease, whereas in our previous paper the outcome was overall breast cancer risk. ER status 
was available for only 73% of the iCOGS and 79% of the OncoArray breast cancer cases (iii) for the set 
of samples genotyped with both arrays, 2 used the iCOGS genotypes, while this study includes 
OncoArray genotypes to maximize the number of samples genotyped with a larger coverage; and (iv) 
the imputation procedure was modified (in particular using one-step imputation without pre-phasing) 
to improve the imputation accuracy of less frequent variants.  
We used a forward stepwise approach to define the number of independent signals within each 
associated genomic region. We first we identified the index variant of the main signal in the region, 
and then ran multinomial logistic regression for all other variants, adjusted by the index variant, to 
identify additional variants that remained independently significant within the model. We repeated 
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this process, adjusting for identified index variants, until no more additional variants could be added.  
In this way we found from 1-11 independent signals within the 150 regions that containing a genome-
wide significant main signal.  
 
Selection of a set of credible causal variants (CCVs) 
For each independently associated signal, we first defined credible candidate variants (CCVs), likely to 
drive its association, as those variants with p-values within two orders of magnitude of the most 
significant variant for that signal, after adjusting for the index variant of other signals within that 
region (as identified in the forward stepwise regression above, Supplementary Figure 6A)24. For each 
region, we then attempted to obtain the best fitting model by successively fitting models in which the 
index variant for each signal was replaced by other CCVs for that signal, adjusting for the index 
variants for the other signals (Supplementary Figure 6B). Where a model with a higher chi-square was 
obtained, the index variant was replaced by the CCV in the best model (Supplementary Figure 6C-D). 
This process was repeated until the model (i.e. the set of index variants) did not change further 
(Supplementary Figure 6G). This procedure was performed first for the set of strong signals (i.e. 
considering models including only the strong signals). Once a final model had been obtained for the 
strong signals, the index variants for the strong signals were considered fixed and the process was 
repeated for all signals, the index variants for the weak signals (but not the strong signals) to vary. 
Using this procedure we could define the best model for 140/150 regions, but for ten regions this 
approach did not converge (chr4:175328036-176346426, chr5:55531884-56587883, chr6:151418856-
152937016, chr8:75730301-76917937, chr10:80341148-81387721, chr10:122593901-123849324, 
chr12:115336522-116336522, chr14:36632769-37635752, chr16:3606788-4606788, chr22:38068833-
39859355). For these 10 regions, we defined the best model, from among all possible combinations of 
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credible variants, as that with the largest chi-square value. Finally, redefined the set of CCVs for each 
signal using the conditional p-values, after adjusting for the revised set of index variants. Again, for 
the strong signals we conditioned on the index variants for the other strong signals, while for the 
weak signals we conditioned on the index variants for all other signals. 
 
Case-only analysis 
Differences in the effect size between ER-positive and ER-negative disease for each index 
independent variant were assessed using a case-only analysis. We performed logistic regression with 
ER status as the dependent variable, and the lead variant at each strong signal in the fine mapping 
region as the independent variables. We use FDR (5%) to adjust for multiple testing. 
 
OncoArray-only stepwise analysis 
To evaluate whether the lower coverage in iCOGS could affect the identification of independent 
signals, we ran stepwise multinomial regression using only the OncoArray dataset. We identified 249 
independent signals. Ninety-two signals, in 67 fine mapping regions, achieved a genome-wide 
significance level (conditional p-value < 5×10-8). Two hundred and five of these signals were also 
identified in the meta-analysis with iCOGS. Nine independent variants across ten regions were not 
evaluated in the combined analysis due to their low imputation info score in iCOGS. Out of these nine 
signals, two signals would be classified as main primary signals, rs114709821 at region 
chr1:145144984-146144984 (OncoArray imputation info score = 0.72), and rs540848673 at region 
chr1:149406413-150420734 (OncoArray imputation info score = 0.33). Given the low number of 
additional signals identified in the OncoArray dataset alone, all analyses were based on the combined 
iCOGS/OncoArray dataset. 
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CIMBA statistical analysis 
CIMBA provided data from 60 retrospective cohort studies consisting of 9,445 unaffected and 9,363 
affected female BRCA1 mutation carriers of European ancestry. Unconditional (i.e. single variant) 
analyses were performed using a score test based on the retrospective likelihood of observing the 
genotype conditional on the disease phenotype 62,63. Conditional analyses, where more than one 
variant is analyzed simultaneously, cannot be performed in this score test framework. Therefore, 
conditional analyses were performed by Cox regression, allowing for adjustment of the conditionally 
independent variants identified by the BCAC/DRIVE analyses. All models were stratified by country 
and birth cohort, and adjusted for relatedness (unconditional models used kinship adjusted standard 
errors based on the estimated kinship matrix; conditional models used cluster robust standard errors 
based on phenotypic family data). 
 
Data from the iCOGS array and the OncoArray were analyzed separately and combined to give an 
overall BRCA1 association by fixed-effects meta-analysis. Variants were excluded from further 
analyses if they exhibited evidence of heterogeneity (Heterogeneity p-value < 1×10-4) between iCOGS 
and OncoArray, had MAF < 0.005, were poorly imputed (imputation info score < 0.3) or were imputed 
to iCOGS only (i.e. must have been imputed to OncoArray or iCOGS and OncoArray). 
 
Meta-analysis of ER-negative cases in BCAC with BRCA1 mutation carriers from CIMBA 
BRCA1 mutation carrier association results were combined with the BCAC multinomial regression ER-
negative association results in a fixed-effects meta-analysis. Variants considered for analysis must 
have passed all prior QC steps and have had MAF≥0.005. All meta-analyses were performed using the 
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METAL software 64.Instances where spurious associations might occur were investigated by assessing 
the LD between a possible spurious association and the conditionally independent variants. High LD 
between a variant and a conditionally independent variant within its region causes model instability 
through collinearity and the convergence of the model likelihood maximization may not reliable. 
Where the association appeared to be driven by collinearity, the signals were excluded. 
 
Heritability Estimation 
To estimate the frailty-scale heritability due to all fine-mapping signals, we used the formula: 
ℎ2 = 2(𝛾′
𝑇
𝑅𝛾′ − 𝜏′
𝑇
𝐼𝜏′) 
here γ′ = γ√p(1 − p), τ′
T
= τ√p(1 − p), where p is a vector of allele frequencies, γ are the 
estimated per-allele odds ratios and τ the corresponding standard errors, and 𝑅 is the correlation 
matrix of genotype frequencies. 
To adjust for the overestimation resulting from only including signals passing a given significance 
threshold, we adapted the approach of 65, based on maximizing the likelihood conditional on the test 
statistic passing the relevant threshold. Since our analyses were based on estimating ER-negative and 
ER-positive odds ratios simultaneously, the method needed to be adapted to maximise a conditional 
bivariate normal likelihood. Following 65 we then estimated mean square error estimates based on a 
weighted mean of the maximum likelihood estimates and the naïve estimates, which they show to be 
close to be unbiased in the 1df case. The estimated effect sizes for overall breast cancer were 
computed as a weighted mean of the ER-negative and ER-positive estimates, based on the 
proportions of each subtype in the whole study (weights 0.21 and 0.79). The results were then 
expressed in terms of the proportion of the familial breast cancer risk (FRR) to first degree relatives of 
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affected women, using the formula  
ℎ2/(2𝑙𝑜𝑔𝜆) where the FRR 𝜆 was assumed to be 2 2. 
 
eQTL analysis 
Total RNA was extracted from normal breast tissue in formalin-fixed paraffin embedded breast cancer 
tissue blocks from 264 Nurses’ Health Study (NHS) participants 32. Transcript expression levels were 
measured using the Glue Grant Human Transcriptome Array version 3.0 at the Molecular Biology Core 
Facilities, Dana-Farber Cancer Institute. Gene expression was normalized and summarized into Log2 
values using RMA (Affymetrix Power Tools v1.18.012); quality control was performed using GlueQC 
and arrayQualityMetrics v3.24.014. Genome-wide data on variants were generated using the Illumina 
HumanHap 550 BeadChip as part of the Cancer Genetic Markers of Susceptibility initiative 66. 
Imputation to the 1000KGP Phase 3 v5 ALL reference panel was performed using MACH to pre-phase 
measured genotypes and minimac to impute. 
 
Expression analyses were performed using data from The Cancer Genome Atlas (TCGA) and Molecular 
Taxonomy of Breast Cancer International Consortium (METABRIC) projects 34,38. The TCGA eQTL 
analysis was based on 458 breast tumors that had matched gene expression, copy number and 
methylation profiles together with the corresponding germline genotypes available. All 458 
individuals were of European ancestry as ascertained using the genotype data and the Local Ancestry 
in admixed Populations (LAMP) software package (LAMP estimate cut-off >95% European)67. Germline 
genotypes were imputed into the 1000 Genomes Project reference panel (October 2014 release) 
using IMPUTE version 2 68,69. Gene expression had been measured on the Illumina HiSeq 2000 RNA-
Seq platform (gene-level RSEM normalized counts 70), copy-number estimates were derived from the 
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Affymetrix SNP 6.0 (somatic copy-number alteration minus germline copy-number variation called 
using the GISTIC2 algorithm 71), and methylation beta values measured on the Illumina Infinium 
HumanMethylation450. Expression QTL analysis focused on all variants within each of the 152 
genomic intervals that had been subjected to fine-mapping for their association with breast cancer 
susceptibility. Each of these variants was evaluated for its association with the expression of every 
gene within 2 Mb that had been profiled for each of the three data types. The effects of tumor copy 
number and methylation on gene expression were first regressed out using a method described 
previously 72. eQTL analysis was performed by linear regression, with residual gene expression as 
outcome, germline SNP genotype dosage as the covariate of interest and ESR1 expression and age as 
additional covariates, using the R package Matrix eQTL 73. 
 
The METABRIC eQTL analysis was based on 138 normal breast tissue samples resected from breast 
cancer patients of European ancestry. Germline genotyping for the METABRIC study was also done on 
the Affymetrix SNP 6.0 array, and gene expression in the METABRIC study was measured using the 
Illumina HT12 microarray platform (probe-level estimates). No adjustment was implemented for 
somatic copy number and methylation status since we were evaluating eQTLs in normal breast tissue. 
All other steps were identical to the TCGA eQTL analysis described above. 
 
Genomic feature enrichment  
We explored the overlap of CCVs and excluded variants with 90 transcription factors, 10 histone 
marks, and DNase hypersensitivity sites in in 15 breast cell lines, and eight normal human breast 
tissues. We analysed data from the Encyclopedia of DNA Elements (ENCODE) Project 74,75, Roadmap 
Epigenomics Projects 76, the International Human Epigenome Consortium 77, 27 , Pellacani et al. 78, The 
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Cancer Genome Atlas (TCGA) 33, the Molecular Taxonomy of Breast Cancer International Consortium 
(METABRIC) 34, ReMap database (We included 241 TF annotations from ReMap (of 2825 total) which 
showed at least 2% overlap for any of the phenotype SNP sets) 79, and other data obtained through 
the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO). 
Promoters were defined following the procedure defined in 78, that is +/- 2Kb from a gene 
transcription start site, using an updated version of the RefSeq genes (refGene, version updated 2017-
04-11)80. Transcribed regions were defined using the same version of refSeq genes. lncRNA 
annotation was obtained from Gencode (v19)81 
 
To include eQTL results in the enrichment analysis we (i) identified all the genes for which summary 
statistics were available; (ii) defined the most significant eQTL variant for each gene (index eQTL 
variant, p-value threshold ≤ 5×10-4); (iii) classified variants with p-values within two orders of 
magnitude of the index eVariant as the credible set of eQTL variants; ie. the best candidates to drive 
expression of the gene. Variants within at least one eQTL credible set were defined as eVariants. We 
evaluated the overlap between eQTL credible sets and CCVs (risk variants credible set). We evaluated 
the enrichment of CCVs for genomic feature using logistic regression, with CCV (vs non-CCV variants) 
being the outcome. To adjust for the correlation among variants in the same fine mapping region, we 
used robust variance estimation for clustered observations (R function multiwaycov). The associated 
variants at FDR 5% were included into a stepwise forward logistic regression procedure to select the 
most parsimonious model. A likelihood ratio test was used to compare multinomial logistic regression 
models with and without equality effect constraints to evaluate whether there was heterogeneity 
among the effect sizes for ER-positive, ER-negative or signals equally associated with both phenotypes 
(ER-neutral). 
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To validate the disease specificity of the regulatory regions identified through this analysis we follow 
the same approach for the autoimmune related CCVs from 29 (N = 4,192). Variants excluded as 
candidate causal variants, and within 500 kb upstream and downstream of the index variant for each 
signal were classified as excluded variants (N = 1,686,484). We then tested the enrichment for both 
the breast cancer and autoimmune CCVs with breast and T and B cell enhancers. We also evaluated 
the overlap of our CCVs with ENCODE enhancer-like and promoter-like regions for 111 tissues, 
primary cells, immortalized cell line, and in vitro differentiated cells. Of these, 73 had available data 
for both enhancer- and promoter-like regions. 
 
Transcription binding site motif analysis 
We conducted a search to find motif occurrences for the transcription factors significantly enriched in 
the genomic featured. For this we used two publicly available databases, Factorbook 82 and JASPAR 
2016 83. For the search using Factorbook we included the motifs for the transcription factors 
discovered in the cell lines where a significant enrichment was found in our genomic features analysis. 
We also searched for all the available motifs for Homo sapiens at the JASPAR database (JASPAR CORE 
2016, TFBSTools 84)Using as reference the USCS sequence (BSgenome.Hsapiens.USCS.hg19) we 
created fasta sequences with the reference and alternative alleles for all the variants included in our 
analysis plus 20 bp flanking each variant. We used FIMO (version 4.11.2, Grant et al., 2011)85 to scan 
all the fasta sequences searching for the JASPAR and Factorbook motifs to identify any overlap of any 
of the alleles for each of the variants (setting the p-value threshold to 10-3). We subsequently 
determined whether our CCVs were more frequency overlapping a particular TF binding motif when 
compared with the excluded variants. We ran these analyses for all the strong signals, but also strong 
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signals stratified by ER status. Also, we subset this analysis to the variants located at regulatory 
regions in an ER-positive cell line (MCF-7 marked by H3K4me1, ENCODE id: ENCFF674BKS) and 
evaluated whether the ER-positive CCVs overlap any of the motifs more frequently that the excluded 
variants. We also evaluated the change in total binding affinity caused by the ER-positive CCCR 
alternative allele for all but one (2:217955891:T:<CN0>:0) of the ER-positive CCVs (MatrixRider 86). 
 
Subsequently, we evaluated whether the MCF-7 regions demarked by H3K4me1 (ENCODE id: 
ENCFF674BKS), and overlapped by ER-positive CCVs, were enriched in known TFBS motifs. We first 
subset the ENCODE bed file ENCFF674BKS to identify MCF-7 H3K4me1 peaks overlapped by the ER-
positive CCVs (N = 107), as well as peaks only overlapped by excluded variants (N = 11,099), using 
BEDTools 87. We created fasta format sequences using genomic coordinate data from the intersected 
bed files. In order to create a control sequence set, we used the script included with the MEME Suite 
(fasta-shuffle-letters) to created 10 shuffled copies of each sequence overlapped by ER-positive CCVs 
(N = 1,070). We then used AME 88 to interrogate whether the 107 MCF-7 H3K4me1 genomic regions 
overlapped by ER-positive CCVs were enriched in know TFBS consensus motifs when compared to the 
shuffled control sequences, or to the MCF-7 H3K4me1 genomic regions overlapped only by excluded 
variants. We used the command line version of AME (version 4.12.0) selecting as scoring method the 
total number of positions in the sequence whose motif score p-value is less than 10-3, and using a 
one-tailed Fisher’s Exact test as the association test. 
 
PAINTOR analysis 
To further refine the set of CCVs, we performed empirical Bayes fine-mapping using PAINTOR to 
integrate marginal genetic association summary statistics, linkage disequilibrium patterns, and 
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biological features 31,89. PAINTOR derives jointly the posterior probability for causality of all variants 
along the respective contribution of genomic features, in order to maximize the log Likelihood of the 
data across all regions. PAINTOR does not assume a fixed number of causal variants in each region, 
although it implicitly penalizes non-parsimonious causal models. We applied PAINTOR separately to 
association results for overall breast cancer (in 85 regions determined to have at least one ER-neutral 
association or ER-positive and ER-negative association), ER-positive breast cancer (in 48 regions 
determined to have at least one ER-positive-specific association), and ER-negative breast cancer (in 22 
regions determined to have at least one ER-negative-specific association). To avoid artifacts due to 
mis-matches between the LD in study samples and the LD matrix supplied to PAINTOR, we used 
association logistic regression summary statistics from OncoArray data only and estimated the LD 
structure in the OncoArray sample. For each endpoint we fit four models with increasing numbers of 
genomic features selected from the stepwise enrichment analyses described above: Model 0 (with no 
genomic features—assumes each variant is equally likely to be causal a priori), Model 1 (with those 
genomic features selected with stopping rule p<0.001); Model 2 (with those genomic features 
selected with stopping rule p<0.01); and Model 3 (with those genomic features selected with stopping 
rule p<0.05).  
 
We used the Bayesian Information Criterion (BIC) to choose the best-fitting model for each outcome. 
As PAINTOR estimates the marginal log likelihood of the observed Z scores using Gibbs sampling, we 
used a shrunk mean BIC across multiple Gibbs chains to account for the stochasticity in the log-
likelihood estimates. We ran PAINTOR four times to generate four independent Gibbs chains and 
estimated the BIC difference between model i and model j as 𝛥𝑖𝑗 = (
100
𝑉+100
) (𝐵𝐼𝐶𝑖´ − 𝐵𝐼𝐶𝑗´ ). This 
assumes a N(0,100) prior on the difference, or roughly a 16% chance that model i would be decisively 
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better than model j (i.e. |BICi-BICj|>10). We then proceeded to choose the best-fitting model in a 
stepwise fashion: starting with a model with no annotations, we selected a model with more 
annotations in favor a model with fewer if the larger model was a considerably better fit—i.e. 𝛥𝑖𝑗  > 2. 
Model 1 was the best fit according to this process for overall and ER-positive breast cancer; Model 0 
was the best fit for ER-negative breast cancer.  
 
Differences between the PAINTOR and CCV outputs may be due to several factors. By considering 
functional enrichment and joint LD among all SNPs, PAINTOR may refine the set of likely causal 
variants; rather than imposing a hard threshold, PAINTOR allows for a gradient of evidence supporting 
causality; and the two sets of calculations are based on different summary statistics, CCV analyses 
used both iCOGS and OncoArray genotypes, while PAINTOR used only OncoArray data (Figure 1, 
Methods). 
 
Variant annotation 
Variants genome coordinates were converted to assembly GRCh38 with liftOver and uploaded to 
Variant Effect Predictor 90 to determine their effect on genes, transcripts, and protein sequence. The 
commercial software Alamut® Batch v1.6 batch was also used to annotate coding and splicing 
variants. PolyPhen-2 91, SIFT 92, MAPP 93 were used to predict the consequence of missense coding 
variants. MaxEntScan 94, Splice-Site Finder, and Human Splicing Finder 95 were used to predict splicing 
effects. 
 
INQUISIT analysis 
Logic underlying INQUISIT predictions 
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Briefly, genes were considered to potential targets of candidate causal variants through effects on: (1) 
distal gene regulation, (2) proximal regulation, or (3) a gene's coding sequence. We intersected CCV 
positions with multiple sources of genomic information including chromatin interactions from capture 
Hi-C experiments performed in a panel of six breast cell lines 96, chromatin interaction analysis by 
paired-end tag sequencing (ChIA-PET; 97) and genome-wide chromosome conformation capture from 
HMECs (Hi-C, (Rao et al., 2014)). We used computational enhancer–promoter correlations (PreSTIGE 
98, IM-PET (He et al., 2014), FANTOM5 99 and super-enhancers 28), results for breast tissue-specific 
expression variants (eVariants) from multiple independent studies (TCGA, METABRIC, NHS, Methods), 
allele-specific imbalance in gene expression 100, transcription factor and histone modification 
chromatin immunoprecipitation followed by sequencing (ChIP-Seq) from the ENCODE and Roadmap 
Epigenomics Projects together with the genomic features found to be significantly enriched as 
described above, gene expression RNA-seq from several breast cancer lines and normal samples and 
topologically associated domain (TAD) boundaries from T47D cells (ENCODE, 101, Methods and Key 
Resources Table ). To assess the impact of intragenic variants, we evaluated their potential to alter 
splicing using Alamut® Batch to identify new and cryptic donors and acceptors, and several tools to 
predict effects of coding sequence changes (see Variant Annotation section). Variants potentially 
affecting post-translational modifications were downloaded from the "A Website Exhibits SNP On 
Modification Event" database (http://www.awesome-hust.com/) 102.  The output from each tool was 
converted to a binary measure to indicate deleterious or tolerated predictions. 
 
Scoring hierarchy 
Each target gene prediction category (distal, promoter or coding) was scored according to different 
criteria. Genes predicted to be distally-regulated targets of CCVs were awarded points based on 
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physical links (eg CHi-C), computational prediction methods, allele-specific expression, or eVariant 
associations. All CCV and HPPVs were considered as potentially involved in distal regulation. 
Intersection of a putative distal enhancer with genomic features found to be significantly enriched 
(see ‘Genomic features enrichment’ for details) were further upweighted. Multiple independent 
interactions were awarded an additional point. CCVs and HPPVs in gene proximal regulatory regions 
were intersected with histone ChIP-Seq peaks characteristic of promoters and assigned to the 
overlapping transcription start sites (defined as -1.0 kb - +0.1 kb). Further points were awarded to 
such genes if there was evidence for eVariant association or allele-specific expression, while a lack of 
expression resulted in down-weighting as potential targets. Potential coding changes including 
missense, nonsense and predicted splicing alterations resulted in addition of one point to the 
encoded gene for each type of change, while lack of expression reduced the score. We added an 
additional point for predicted target genes that were also breast cancer drivers. For each category, 
scores ranged from 0-7 (distal); 0-3 (promoter) or 0-2 (coding). We converted these scores into 
'confidence levels': Level 1 (highest confidence) when distal score > 4, promoter score >= 3 or coding 
score > 1; Level 2 when distal score <=  4 and >=1, promoter score = 1 or = 2, coding score = 1; and 
Level 3 when distal score < 1 and > 0, promoter score < 1 and > 0, and coding < 1 and > 0. For genes 
with multiple scores (for example, predicted as targets from multiple independent risk signals or 
predicted to be impacted in several categories), we recorded the highest score. Driver and 
transcription factor gene enrichment analysis was carried out using INQUISIT scores prior to adding a 
point for driver gene status. Modifications to the pipeline since original publication 2 include: 
 TAD boundary definitions from ENCODE T47D Hi-C analysis. Previously, we used regions from Rao, 
Cell 2013; 
 eQTL: Addition of NHS normal and tumor samples 
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 allele-specific imbalance using TCGA and GTEx RNA-seq data 100 
 Capture Hi-C data from six breast cell lines 103 
 Additional biofeatures derived from global enrichment in this study 
 Variants affecting sites of post-translational modification 102 
 
Multi-signal targets 
To test if more genes were targeted by multiple signals than expected by chance, we modelled the 
number of signals per gene by negative binomial regression (R function glm.nb, package MASS) and 
Poisson regression (R function glm, package stats) with ChIA-PET interactions as a covariate and 
adjusted by fine mapping region. Likelihood ratio tests were used to compare goodness of fit. 
Rootograms were created using the R function rootogram (package vcd).  
 
Pathway analysis 
The pathway gene set database, dated 1 September 2018 was used 104 
(http://download.baderlab.org/EM_Genesets/current_release/Human/symbol/). This database 
contains pathways from Reactome 105, NCI Pathway Interaction Database 106, GO (Gene Ontology) 107, 
HumanCyc 108, MSigdb 109, NetPath 110, and Panther 111. All duplicated pathways, defined in two or 
more databases, were included. To provide more biologically meaningful results, only pathways that 
contained ≤ 200 genes were used.  
We interrogated the pathway annotation sets with the list of high-confidence (Level 1) INQUISIT gene 
list. The significance of over-representation of the INQUISIT genes within each pathway was assessed 
with a hypergeometric test using the R function phyper as follows: 
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where x is the number of Level 1 genes that overlap with any of the genes in the pathway, n is the 
number of genes in the pathway, m is the number of Level1 genes that overlap with any of the genes 
in the pathway data set (mstrong GO = 145, mER-positive GO = 50, mER-negative GO = 27, mER-neutral GO = 73; mstrong 
Pathways = 121, mER-positive Pathways = 38, mER-negative Pathways = 21, mER-neutral Pathways = 68), and N is the number 
of genes in the pathway data set (NGenes GO = 14,252, NGenes Pathways = 10,915). We only included 
pathways that overlapped with at least two Level 1 genes. We used the Benjamini-Hochberg false 
discovery rate (FDR) 112 at 5% level.  
 
DATA AVAILABLITY 
The credible set of causal variants (determined by either multinomial stepwise regression and 
PAINTOR) is provided in Supplementary Table S2C. Further information and requests for resources 
should be directed to Manjeet Bolla (bcac@medschl.cam.ac.uk) 
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FIGURE LEGENDS 
Figure 1. Flowchart summarizing the study design. 
Logistic regression summary statistics were used to select the final set of variants to run 
stepwise multinomial regression. These results were meta-analysed with CIMBA to provide the 
final set of strong independent signals and their CCVs. Through a case-only analysis we 
identified significant differences in effect sizes between ER-positive and ER-negative breast 
cancer and used this to classify the phenotype for each independent signal. With these strong 
CCVs, we ran the bio-features enrichment analysis, which identified the features to be included 
in the PAINTOR models, together with the OncoArray logistic regression summary statistics, and 
the OncoArray LD. Both multinomial regression CCVs and PAINTOR high Posterior Probability 
variants were analyzed with INQUISIT to determine high confidence target genes. Finally, we 
used the set of high confidence target genes to identify enriched pathways. 
a  conditional on the index variants from BCAC strong signals. 
 
Figure 2. Determining independent risk signals and credible candidate variants (CCVs). 
(a) Number of independent signals per region identified through multinomial stepwise logistic 
regression. (b) Signal classification according to their confidence into strong and moderate 
confidence signals. (c) Number of CCVs per signal at strong confidence signals identified 
through multinomial stepwise logistic regression. (d) Number of CCVs per signal at moderate 
confidence signals identified through multinomial stepwise regression. (e) Subtype classification 
of strong signals into ER-positive, ER-negative and signals equally associated with both 
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phenotypes (ER-neutral) from BCAC analysis. (f) Subtype classification from the meta-analysis of 
BCAC and CIMBA. Between brackets, number of CCVs from the meta-analysis of BCAC and 
CIMBA. (g) Number of variants at different posterior probability thresholds. 15 variants reach a 
PP ≥ 80% by at least one of the three models (ER-all, ER-positive, ER-negative). 
 
Figure 3. Overlap of CCVs with gene regulatory regions gene bodies and transcription factor 
binding sites. 
(a) Breast cancer CCVs overlap with chromatin states and broad breast cells epigenetic marks. 
(b) Breast cancer CCVs overlap with breast cells epigenetic marks. (c) Autoimmune CCVs 
overlap with breast cells epigenetic marks. (d) Breast cancer CCVs overlap with autoimmune-
related epigenetic marks. (e) Autoimmune CCVs overlap with autoimmune-related epigenetic 
marks. (f) Significant ER-positive CCVs overlap with transcription factors binding sites. TFBSs 
found significant for ER-positive CCVs are highlighted in red (x axis labels). (g) Significant ER-
negative CCVs overlap with transcription factors binding sites. (h) Significant ER-neutral CCVs 
overlap with transcription factors binding sites. Strong column: analysis with all CCVs at strong 
signals. ER-positive, ER-negative, ER-neutral: analysis of CCVs at strong signals stratified by 
phenotype. Logistic regression robust variance estimation for clustered observations, Wald test 
2 p-values estimated using 67,136 ER-positive and 17,506 ER-negative cases, together with 
88,937 controls. 
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Non-significant p-values are noted as dark grey. Significance defined as FDR 5%, which 
corresponds to the following P-value thresholds: Strong signals P-value = 1.66x10-2, ER-positive 
P-value = 2.42x10-2; ER-negative P-value 3.02x10-3; ER-neutral P-value = 1.76x10-3.  
 
Figure 4. Predicted target genes are enriched in known breast cancer driver genes and 
transcription factors. 
79 target genes that fulfil at least one of the following criteria: are targeted by more than one 
independent signal, are known driver genes, transcription factor genes, or their binding sites 
(ChIP-Seq BS) or consensus motif (TF Motif) are significantly overlapped by CCVs. *Genes with 
published functional follow up.  
 
Figure 5. Predicted target genes by phenotype and significantly enriched pathways. 
(a) Venn diagram showing the associated phenotype (ER-positive, ER-negative, ER-neutral) for 
the Level 1 target genes, predicted by the CCVs and HPPVs. * ER-positive or ER-negative target 
genes also targeted by ER-neutral signals. (b) Heatmap showing clustering of pathway themes 
over-represented by INQUISIT Level 1 target genes. Color represents the relative number of 
genes per phenotype within enriched pathways, grouped by common themes. ER-positive, ER-
negative, ER-neutral, and all phenotypes together (strong).
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Table 1. Signals with single CCVs and variants with PP > 80%  
                ER-negative  ER-positive       
 
Fine-mapping 
regiona 
Variant b Ref/Alt c EAFd PPe Modelf Signalg 
N 
CCVh 
ORi (95%CI) ORi (95%CI) P-valuei FPj 
Predicted 
target gene(s)k 
Confidencel 
chr1:120723447 
-121780613 
rs11249433 A/G 0.42 0.57 ERALL Signal 1 1 1.02 (0.99-1.04) 1.13 (1.11-1.15) 8.11x10-60 na na  
chr1:200937832 
-201937832 
rs35383942 C/T 0.06 0.96 ERALL Signal 1 2 1.10 (1.05-1.16) 1.09 (1.06-1.13) 1.14x10-7 D TNNI1 Level 1 
chr2:201681247 
-202681247 
rs3769821 C/T 0.66 0.40 ERALL Signal 1 1 0.94 (0.92-0.97) 0.95 (0.93-0.96) 1.46x10-12 D ALS2CR12 Level 1 
chr2:217405832 
-218796508 
rs4442975 n G/T 0.48 0.84 ERALL Signal 1 1 0.94 (0.92-0.97) 0.86 (0.85-0.87) 2.50x10-90 D IGFBP5m Level 2 
chr4:105569013 
-106856761 
esv3601665 -/Alu 0.07 0.95 ERPOS 
  
1.01 (0.95-1.08) 1.10 (1.06-1.14) 3.27x10-6 D ARHGEF38, AC004066.3 Level 1 
chr5:779790 
-1797488 
rs10069690 C/T 0.27 0.58 ERNEG Signal 1 1 1.18 (1.15-1.21) 1.03 (1.01-1.05) 1.20x10-34 D SLC6A18, TERTm Level 2 
chr5:44013304 
-45206498 
rs10941679 A/G 0.26 0.00 ERPOS Signal 1 1 1.04 (1.02-1.07) 1.17 (1.15-1.19) 1.50x10-77 D MRPS30 Level 2 
 
rs5867671 A/- 0.77 0.01 ERPOS Signal 2 1 0.91 (0.89-0.94) 0.99 (0.97-1.01) 2.25x10-9 na na  
chr5:44013304 
-45206498 
rs190443933 T/C 0.01 0.00 ERALL Signal 4 1 1.30 (1.14-1.48) 1.26 (1.16-1.37) 2.32x10-8 na na  
chr5:55531884 
-56587883 
rs984113 G/C 0.61 0.81 ERPOS Signal 2 1 0.96 (0.93-0.98) 0.96 (0.94-0.97) 3.51x10-8 D MAP3K1m Level 2 
 
 
rs889310 C/T 0.56 0.84 ERPOS (Signal 6) 15 1.03 (1.00-1.05) 1.05 (1.03-1.06) 1.75x10-7 D MAP3K1m Level 1 
chr6:15899557 
-16899557 
rs3819405 C/T 0.32 0.96 ERALL Signal 1 1 0.97 (0.95-1.00) 0.95 (0.94-0.97) 1.14x10-7 D 
ATXN1, RP1-151F17.1, 
RP1-151F17.2 
Level 2 
chr6:151418856 
-152937016 
rs12173562 C/T 0.08 0.10 ERNEG Signal 1 1 1.30 (1.25-1.36) 1.14 (1.11-1.18) 3.98x10-40 D ESR1m Level 1 
 
rs34133739 -/C 0.53 0.25 ERALL Signal 2 1 1.11 (1.09-1.14) 1.05 (1.04-1.07) 2.36x10-22 D ESR1m Level 1 
 
rs851984 G/A 0.40 0.73 ERALL Signal 3 1 1.07 (1.04-1.09) 1.05 (1.04-1.07) 3.69x10-13 D ESR1m Level 1 
chr7:130167121 
-131167121 
rs68056147 G/A 0.30 0.84 ERALL 
  
1.04 (1.01-1.07) 1.05 (1.03-1.06) 3.07x10-7 D MKLN1 Level 2 
chr8:127424659 
-130041931 
rs35961416 -/A 0.41 0.68 ERALL Signal 3 1 0.97 (0.94-0.99) 0.95 (0.93-0.96) 9.97x10-11 D MYCm Level 1 
chr9:21247803 
-22624477 
rs539723051 AAAA/- 0.33 0.43 ERALL Signal 1 1 1.08 (1.05-1.11) 1.06 (1.04-1.08) 1.81x10-15 na na  
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chr9:109803808 
-111395353 
rs10816625 A/G 0.07 0.95 ERPOS Signal 3 1 1.06 (1.01-1.11) 1.13 (1.10-1.16) 3.62x10-15 D KLF4m Level 2 
 
rs13294895 C/T 0.18 0.93 ERPOS Signal 4 1 1.01 (0.98-1.05) 1.09 (1.07-1.11) 4.00x10-17 D KLF4m Level 1 
chr9:109803808 
-111395353 
rs60037937 AA/- 0.22 0.68 ERPOS Signal 2 1 1.02 (0.99-1.06) 1.11 (1.09-1.13) 3.17x10-26 D KLF4m, RAD23B Level 2 
chr10:63758684 
-65063702 
rs10995201 A/G 0.15 0.31 ERALL Signal 1 1 0.91 (0.88-0.94) 0.87 (0.85-0.89) 1.40x10-37 na na  
chr10:122593901 
-123849324 
rs35054928 C/- 0.56 0.60 ERALL Signal 1 1 0.96 (0.94-0.98) 0.74 (0.73-0.76) 6.55x10-342 D FGFR2m Level 1 
 
rs45631563 n A/T 0.04 0.93 ERPOS Signal 3 1 0.97 (0.92-1.03) 0.76 (0.73-0.79) 4.84x10-44 C FGFR2m Level 2 
 
rs7899765 T/C 0.06 0.02 ERALL Signal 5 1 1.01 (0.97-1.06) 0.87 (0.84-0.90) 2.21x10-18 D FGFR2m Level 1 
chr11:68831418 
-69879161 
rs78540526 C/T 0.09 0.91 ERPOS Signal 1 1 1.01 (0.97-1.06) 1.40 (1.36-1.44) 2.77x10-145 D CCND1m, MYEOV Level 1 
chr12:27639846 
-29034415 
rs7297051 C/T 0.23 0.23 ERALL Signal 1 1 0.87 (0.85-0.90) 0.89 (0.88-0.91) 3.12x10-43 D 
CCDC91m, PTHLHm, 
RP11-967K21.1 
Level 2 
chr12:115336522 
-116336522 
rs35422 G/A 0.57 0.58 ERPOS Signal 2 1 0.98 (0.96-1.01) 1.05 (1.03-1.07) 4.85x10-10 D TBX3 Level 1 
chr14:91341069 
-92368623 
rs7153397 C/T 0.70 0.81 ERPOS Signal 1 3 1.01 (0.99-1.04) 1.06 (1.04-1.08) 3.25x10-11 D,C 
CCDC88C, CTD-2547L24.4, 
C14orf159, GPR68, RPS6KA5, 
RP11-73M18.7, RP11-895M11.3 
Level 2 
chr16:52038825 
-53038825 
rs4784227 C/T 0.27 0.95 ERPOS Signal 1 1 1.15 (1.12-1.18) 1.26 (1.24-1.28) 4.63x10-160 D TOX3m Level 1 
chr18:23832476 
-25075396 
rs180952292 T/C 0.01 0.01 ERNEG Signal 4 1 1.24 (1.12-1.37) 0.98 (0.92-1.05) 2.07x10-5 na na  
chr18:41899590 
-42899590 
rs9952980 T/C 0.34 0.95 ERALL Signal 2 3 0.97 (0.94-0.99) 0.95 (0.93-0.96) 7.43x10-12 D SLC14A2 Level 2 
chr20:5448227 
-6448227 
rs16991615 G/A 0.07 0.97 ERALL Signal 1 1 1.09 (1.04-1.15) 1.07 (1.04-1.11) 7.89x10-7 D, C GPCPD1, MCM8 Level 2 
chr22:45783297 
-46783297 
rs184070480 C/T 0.01 0.00 ERALL Signal 2 1 1.40 (1.20-1.64) 1.01 (0.91-1.12) 5.02x10-5 D ATXN10, WNT7B Level 2 
 
a GRCh37/hg19, bp 
b Current reference ID  
c Reference (Ref) versus Alternative (Alt) Allele 
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d Effect allele (Alt allele) frequency in OncoArray 
e PP: Posterior probability. Largest posterior probability in all evaluated models 
f Model where the variant reaches the largest posterior probability 
g Signal where the variant is included. Between brackets moderate confidence signals. 
h Number of CCVs in the signal 
i Multinomial logistic regression summary statistics, 2 single variant analysis p-value, estimated using 67,136 ER-positive and 17,506 
ER-negative cases, together with 88,937 controls.  
j D: Distal regulation, P: proximal regulation, C: coding; na: prediction non available 
k Predicted target genes with the largest confidence level for each variant. Between brackets, largest confidence level. na: prediction 
non available 
l INQUISIT level of confidence 
m Target genes with functional follow up 
n Two variants reach PP> 0.8 in both the ERall and ERpos models; rs4442975: ERpos PP = 0.83, ERall PP = 0.84; rs45631563: ERpos PP 
= 0.93, ERall PP = 0.92 
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Editorial summary: Fine-mapping of causal variants and integration of epigenetic and chromatin conformation data identify likely target 
genes for 150 breast cancer risk regions. 
 1 
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes 
 
SUPPLEMENTARY INFORMATION  
  
Supplementary Excel Table guide, supplied as individual files  
Supplementary Table 1. Breast cancer risk regions identified through genome-wide 
association studies.  
(a) Definition of fine-mapping regions based on previous results. 179 variants across 152 
genomic regions. Variants located less than 500kb away from each other were included in the 
same region. (b) Imputation quality metrics across the 152 fine-mapping regions.  
Supplementary Table 2. Breast cancer risk signals and credible candidate variants (CCVs).  
(a) Multinomial Logistic Regression models. (b) Strong signals (BCAC and CIMBA) multinomial 
logistic regression models. (c) Candidate causal variants and high posterior probability 
variants. 
Multinomial logistic regression summary statistics 2 p-value, estimated using 67,136 ER-
positive and 17,506 ER-negative cases, together with 88,937 controls 
Supplementary Table 3. Bio-features enrichment. 
Logistic regression robust variance estimation for clustered observations, Wald test 2 p-
values estimated using 67,136 ER-positive and 17,506 ER-negative cases, together with 
88,937 controls. 
Supplementary Table 4. Consensus transcription factor binding motif enrichment.  
(a) Transcription Factor consensus binding motif enrichment analysis. (b) Transcription Factor 
enrichment at MCF-7 H3K4me1 regions. (c) ER-positive CCVs overlap with transcription factor 
binding motifs significantly enriched  
 2 
Logistic regression, Wald test 2 p-values estimated using 67,136 ER-positive and 17,506 ER-
negative cases, together with 88,937 controls. 
Supplementary Table 5. Coding, splicing CCVs and overlap of CCVs with variant drivers of local 
gene expression.  
(a) CCVs collocating with eQTL variants in normal breast tissue. (b) CCVs collocating 
with eQTL variants in breast tumor tissue. (c) CCVs coding annotation. (d) CCVs predicted to 
affect splicing  
Logistic regression robust variance estimation for clustered observations, Wald test 2 p-
values estimated using 67,136 ER-positive and 17,506 ER-negative cases, together with 
88,937 controls. 
Supplementary Table 6. (a) 191 Level 1 predicted target genes. (b) Regions in which target 
genes are predicted with high confidence 
Supplementary Table 7. INQUISIT results for coding/splicing variants.  
Supplementary Table 8. INQUISIT results for promoter variants.  
Supplementary Table 9. INQUISIT results for distal variants.  
Supplementary Table 10. Pathways significantly enriched in CCV and high posterior 
probability predicted target genes. 
Hypergeometric test p-value. P-values adjusted using Benjamini-Hochberg procedure 
Supplementary Table 11. BCAC studies ethical agreements 
Supplementary Table 12. CIMBA studies ethical agreements 
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Supplementary Figures 
 
Supplementary Figure 1. Bio-features enrichment  
(a) Intersection between CCVs and known bio-features. (b) ENCODE enhancer-like and 
promoter-like enrichment. ENCODE enhancer-like regions, top, ENCODE promoter like tissues, 
bottom. Each bar shows the overlap p-value for each subset of CCVs (Strong, ER-positive, ER-
negative and ER-neutral) with regulatory regions defined by ENCODE at 73 tissues, primary 
cells, immortalized cell line, and in vitro differentiated cells (from most significant, dark red, 
to less significant, blue; grey bars indicate regions where there is <5 CCVs overlapping the 
region) 
Logistic regression robust variance estimation for clustered observations, Wald test 2 p-
values estimated using 67,136 ER-positive and 17,506 ER-negative cases, together with 
88,937 controls. 
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 6 
Supplementary Figure 2. Correlation between variants overlapping significantly enriched 
bio-features 
Ranges of Correlation Coefficient values (Pearson's r) estimated using 639,118 variants 
overlapping enriched biofeatures are denoted by colours as shown in the key labelled: Coeff. 
  
  
Human Mammary Epithelial Cell H3K27me3
184−hTert−L9 H3K27me3
184−hTert−L2 H3K27me3
MCF−10A H3K27me3
Breast fibroblast H3K27me3
Luminal H3K27me3
Luminal Progenitor H3K27me3
Basal H3K27me3
Stroma H3K27me3
MCF−7 Heterochromatin
184−hTert−L2 H3K9me3
Luminal H3K9me3
MCF−7 ESR1
normal breast eVariant
Breast tumour eVariant
Human Mammary Epithelial Cell H3K36me3
vHMEC H3K36me3
MCF−10A H3K36me3
Human Mammary Epithelial Cell H3K79me2
Canonical genes
transcribed region
HMEC H3K27ac
HMEC H3k4me3
HMEC H3K9ac
Breast Myoepithelial H3K9ac
MCF−7 MYC
MCF−7 PML
MCF−10A POLR2A
MCF−7 HA−E2F1
MCF−7 E2F1
HMEC Enhancer CTCF
MCF−7 RAD21
HCC2157 KDM5B
MDA−MB−453 FOXA1
T−47D EGLN2
T−47D ARNT
T−47D Open Chromatin
MCF−7 Open Chromatin
MCF−7 HCFC1
MCF−7 DPF2
MCF−7 CTBP1
Human Mammary Epithelial Cell H3K4me3
T−47D H3K4me3
MCF−7 H3K4me2
MCF−7 H3K4me3
TFBS
MCF−7 PBX1
MCF−7 H3K27ac
MCF−7 H3K4me1
MCF−10A H3k4me1
vHMEC H3K4me1
Luminal H3K4me1
Luminal H3K27ac
MCF−10A PGR
T−47D PGR
HCC1395 BRD4
Breast fibroblast Open Chromatin
MCF−10A STAT3
MCF−10A FOS
Human Mammary Epithelial Cell Open Chromatin
MCF−10A MYC
vHMEC Open Chromatin
MCF−7 ZBTB11
MCF−7 FOXM1
MCF−7 AR
MCF−7 ESR2
T−47D ESR1
MCF−7 NRIP1
MCF−7 NCOA3 (SRC3)
MCF−7 POLR2A
MCF−7 TEAD4
MCF−7 EP300
MCF−7 TCF12
ZR−75−1 ESR1
ER binding site
MCF−7 NR2F2
MCF−7 NR3C1
MCF−7 FOXA1
MCF−7 RARA
MCF−7 RARG
MCF−7 Enhancers
MCF−7 CEBPB
MCF−7 SIN3A
MCF−7 HDAC2
MCF−7−LTED Open Chromatin
MCF−7 JUND
MCF−7 GATA3
ZR−75−1 FOXA1
ZR−75−1 NR3C1
T−47D GATA3
MCF−7 TCF7L2
MCF−7 ZNF217
T−47D JUND
T−47D BRD4
T−47D EP300
T−47D,ZR−75−1,MCF−7 FOXA1
T−47D FOXA1
MCF−7 AHR
SK−BR−3 ESRRA
BT−474 ESRRA
MDA−MB−453 TCF7L2
MCF−7 TFAP2C
BT−474 TFAP2C
SK−BR−3 TFAP2C
Breast tumour ESR1
MCF−7 PGR
MCF−7 CREBBP
MDA−MB−453 AR
H
um
an
 M
am
m
ar
y 
E
pi
th
el
ia
l C
el
l H
3K
27
m
e3
18
4−
hT
er
t−
L9
 H
3K
27
m
e3
18
4−
hT
er
t−
L2
 H
3K
27
m
e3
M
C
F−
10
A 
H
3K
27
m
e3
B
re
as
t f
ib
ro
bl
as
t H
3K
27
m
e3
Lu
m
in
al
 H
3K
27
m
e3
Lu
m
in
al
 P
ro
ge
ni
to
r H
3K
27
m
e3
B
as
al
 H
3K
27
m
e3
S
tro
m
a 
H
3K
27
m
e3
M
C
F−
7 
H
et
er
oc
hr
om
at
in
18
4−
hT
er
t−
L2
 H
3K
9m
e3
Lu
m
in
al
 H
3K
9m
e3
M
C
F−
7 
E
S
R
1
no
rm
al
 b
re
as
t e
Va
ria
nt
B
re
as
t t
um
ou
r e
Va
ria
nt
H
um
an
 M
am
m
ar
y 
E
pi
th
el
ia
l C
el
l H
3K
36
m
e3
vH
M
EC
 H
3K
36
m
e3
M
C
F−
10
A 
H
3K
36
m
e3
H
um
an
 M
am
m
ar
y 
E
pi
th
el
ia
l C
el
l H
3K
79
m
e2
C
an
on
ic
al
 g
en
es
tra
ns
cr
ib
ed
 re
gi
on
H
M
E
C
 H
3K
27
ac
H
M
EC
 H
3k
4m
e3
H
M
E
C
 H
3K
9a
c
B
re
as
t M
yo
ep
ith
el
ia
l H
3K
9a
c
M
C
F−
7 
M
Y
C
M
C
F−
7 
PM
L
M
C
F−
10
A
 P
O
LR
2A
M
C
F−
7 
H
A−
E
2F
1
M
C
F−
7 
E
2F
1
H
M
E
C
 E
nh
an
ce
r C
TC
F
M
C
F−
7 
R
AD
21
H
C
C
21
57
 K
D
M
5B
M
D
A−
M
B−
45
3 
FO
X
A1
T−
47
D
 E
G
LN
2
T−
47
D
 A
R
N
T
T−
47
D
 O
pe
n 
C
hr
om
at
in
M
C
F−
7 
O
pe
n 
C
hr
om
at
in
M
C
F−
7 
H
C
FC
1
M
C
F−
7 
D
P
F2
M
C
F−
7 
C
TB
P
1
H
um
an
 M
am
m
ar
y 
E
pi
th
el
ia
l C
el
l H
3K
4m
e3
T−
47
D
 H
3K
4m
e3
M
C
F−
7 
H
3K
4m
e2
M
C
F−
7 
H
3K
4m
e3
TF
B
S
M
C
F−
7 
P
BX
1
M
C
F−
7 
H
3K
27
ac
M
C
F−
7 
H
3K
4m
e1
M
C
F−
10
A 
H
3k
4m
e1
vH
M
EC
 H
3K
4m
e1
Lu
m
in
al
 H
3K
4m
e1
Lu
m
in
al
 H
3K
27
ac
M
C
F−
10
A
 P
G
R
T−
47
D
 P
G
R
H
C
C
13
95
 B
R
D
4
Br
ea
st
 fi
br
ob
la
st
 O
pe
n 
C
hr
om
at
in
M
C
F−
10
A 
ST
AT
3
M
C
F−
10
A 
FO
S
H
um
an
 M
am
m
ar
y 
E
pi
th
el
ia
l C
el
l O
pe
n 
C
hr
om
at
in
M
C
F−
10
A
 M
Y
C
vH
M
E
C
 O
pe
n 
C
hr
om
at
in
M
C
F−
7 
ZB
TB
11
M
C
F−
7 
FO
XM
1
M
C
F−
7 
A
R
M
C
F−
7 
E
S
R
2
T−
47
D
 E
S
R
1
M
C
F−
7 
N
R
IP
1
M
C
F−
7 
N
C
O
A3
 (S
R
C
3)
M
C
F−
7 
P
O
LR
2A
M
C
F−
7 
TE
A
D
4
M
C
F−
7 
EP
30
0
M
C
F−
7 
TC
F1
2
ZR
−7
5−
1 
E
S
R
1
E
R
 b
in
di
ng
 s
ite
M
C
F−
7 
N
R
2F
2
M
C
F−
7 
N
R
3C
1
M
C
F−
7 
FO
XA
1
M
C
F−
7 
R
AR
A
M
C
F−
7 
R
A
R
G
M
C
F−
7 
En
ha
nc
er
s
M
C
F−
7 
C
E
B
P
B
M
C
F−
7 
SI
N
3A
M
C
F−
7 
H
D
AC
2
M
C
F−
7−
LT
E
D
 O
pe
n 
C
hr
om
at
in
M
C
F−
7 
JU
N
D
M
C
F−
7 
G
AT
A
3
ZR
−7
5−
1 
FO
XA
1
ZR
−7
5−
1 
N
R
3C
1
T−
47
D
 G
AT
A
3
M
C
F−
7 
TC
F7
L2
M
C
F−
7 
ZN
F2
17
T−
47
D
 J
U
N
D
T−
47
D
 B
R
D
4
T−
47
D
 E
P
30
0
T−
47
D,
ZR
−7
5−
1,
M
C
F−
7 
FO
X
A1
T−
47
D
 F
O
XA
1
M
C
F−
7 
AH
R
S
K
−B
R
−3
 E
S
R
R
A
BT
−4
74
 E
S
R
R
A
M
D
A
−M
B
−4
53
 T
C
F7
L2
M
C
F−
7 
TF
A
P
2C
BT
−4
74
 T
FA
P
2C
S
K−
B
R
−3
 T
FA
P
2C
Br
ea
st
 tu
m
ou
r E
S
R
1
M
C
F−
7 
P
G
R
M
C
F−
7 
C
R
E
B
B
P
M
D
A−
M
B−
45
3 
AR
−1.0
−0.5
0.0
0.5
1.0
Corr
 7 
Supplementary Figure 3. Bayesian fine mapping  
Top: Number of Variants per total posterior probability (PP) from PAINTOR models for (a) ER-
all model (b) ER-positive (c) ER-negative.  
Bottom: Cumulative distributions of PP for variants in strong signals for overall breast cancer 
(d, green), strong signals for ER-positive breast cancer (e, blue), and strong signals for ER-
negative breast cancer (f, red), compared to cumulative distributions of variants outside of 
these signals (black).  
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Supplementary Figure 4. Predicted target genes enrichment analysis  
(a) Predicted target genes are enriched in known breast cancer driver genes and TFs. (b) 
Hanging rootograms for the negative binomial model (glm.ng), and the Poisson model 
(glm.pois). The red line represents the expected counts given the model. The bars denote the 
observed counts. X-axis shows the count bin. Y-axis shows the square root of the observed or 
expected count  
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Supplementary Figure 5. Examples of INQUISIT using genomic features to identify predict target genes. 
In each panel, CCVs and PAINTOR variants with posterior probability >0.3 are shown, with independent signals in different colors. Chromatin 
interactions are shown as arcs (Capture Hi-C from selected breast cell lines) or boxes connected by lines, colored with gray-scale according to 
interaction score (ENCODE ChIA-PET). Biofeatures which overlap CCVs from the global genomic enrichment analysis are depicted as red boxes. 
Computationally predicted enhancers including PreSTIGE, FANTOM5 and super-enhancers which overlap risk variants are represented by black 
boxes. High confidence INQUISIT target gene predictions include NRIP1 (b), CHEK2 and XBP1 (c), and RPLP0 and MSI1 (d) 
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Supplementary Figure 6. Selection of a set of credible causal variants 
Scheme of the forward stepwise procedure to define a set of credible causal variants 
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